Cargando…

Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H

Botulinum neurotoxins (BoNTs), which have been exploited as cosmetics and muscle-disorder treatment medicines for decades, are well known for their extreme neurotoxicity to humans. They pose a potential bioterrorism threat because they cause botulism, a flaccid muscular paralysis-associated disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Guorui, Lam, Kwok-ho, Perry, Kay, Weisemann, Jasmin, Rummel, Andreas, Jin, Rongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371848/
https://www.ncbi.nlm.nih.gov/pubmed/28282873
http://dx.doi.org/10.3390/toxins9030093
_version_ 1782518504776269824
author Yao, Guorui
Lam, Kwok-ho
Perry, Kay
Weisemann, Jasmin
Rummel, Andreas
Jin, Rongsheng
author_facet Yao, Guorui
Lam, Kwok-ho
Perry, Kay
Weisemann, Jasmin
Rummel, Andreas
Jin, Rongsheng
author_sort Yao, Guorui
collection PubMed
description Botulinum neurotoxins (BoNTs), which have been exploited as cosmetics and muscle-disorder treatment medicines for decades, are well known for their extreme neurotoxicity to humans. They pose a potential bioterrorism threat because they cause botulism, a flaccid muscular paralysis-associated disease that requires immediate antitoxin treatment and intensive care over a long period of time. In addition to the existing seven established BoNT serotypes (BoNT/A–G), a new mosaic toxin type termed BoNT/HA (aka type FA or H) was reported recently. Sequence analyses indicate that the receptor-binding domain (H(C)) of BoNT/HA is ~84% identical to that of BoNT/A1. However, BoNT/HA responds differently to some potent BoNT/A-neutralizing antibodies (e.g., CR2) that target the H(C). Therefore, it raises a serious concern as to whether BoNT/HA poses a new threat to our biosecurity. In this study, we report the first high-resolution crystal structure of BoNT/HA-H(C) at 1.8 Å. Sequence and structure analyses reveal that BoNT/HA and BoNT/A1 are different regarding their binding to cell-surface receptors including both polysialoganglioside (PSG) and synaptic vesicle glycoprotein 2 (SV2). Furthermore, the new structure also provides explanations for the ~540-fold decreased affinity of antibody CR2 towards BoNT/HA compared to BoNT/A1. Taken together, these new findings advance our understanding of the structure and function of this newly identified toxin at the molecular level, and pave the way for the future development of more effective countermeasures.
format Online
Article
Text
id pubmed-5371848
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53718482017-04-10 Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H Yao, Guorui Lam, Kwok-ho Perry, Kay Weisemann, Jasmin Rummel, Andreas Jin, Rongsheng Toxins (Basel) Article Botulinum neurotoxins (BoNTs), which have been exploited as cosmetics and muscle-disorder treatment medicines for decades, are well known for their extreme neurotoxicity to humans. They pose a potential bioterrorism threat because they cause botulism, a flaccid muscular paralysis-associated disease that requires immediate antitoxin treatment and intensive care over a long period of time. In addition to the existing seven established BoNT serotypes (BoNT/A–G), a new mosaic toxin type termed BoNT/HA (aka type FA or H) was reported recently. Sequence analyses indicate that the receptor-binding domain (H(C)) of BoNT/HA is ~84% identical to that of BoNT/A1. However, BoNT/HA responds differently to some potent BoNT/A-neutralizing antibodies (e.g., CR2) that target the H(C). Therefore, it raises a serious concern as to whether BoNT/HA poses a new threat to our biosecurity. In this study, we report the first high-resolution crystal structure of BoNT/HA-H(C) at 1.8 Å. Sequence and structure analyses reveal that BoNT/HA and BoNT/A1 are different regarding their binding to cell-surface receptors including both polysialoganglioside (PSG) and synaptic vesicle glycoprotein 2 (SV2). Furthermore, the new structure also provides explanations for the ~540-fold decreased affinity of antibody CR2 towards BoNT/HA compared to BoNT/A1. Taken together, these new findings advance our understanding of the structure and function of this newly identified toxin at the molecular level, and pave the way for the future development of more effective countermeasures. MDPI 2017-03-08 /pmc/articles/PMC5371848/ /pubmed/28282873 http://dx.doi.org/10.3390/toxins9030093 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yao, Guorui
Lam, Kwok-ho
Perry, Kay
Weisemann, Jasmin
Rummel, Andreas
Jin, Rongsheng
Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H
title Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H
title_full Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H
title_fullStr Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H
title_full_unstemmed Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H
title_short Crystal Structure of the Receptor-Binding Domain of Botulinum Neurotoxin Type HA, Also Known as Type FA or H
title_sort crystal structure of the receptor-binding domain of botulinum neurotoxin type ha, also known as type fa or h
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371848/
https://www.ncbi.nlm.nih.gov/pubmed/28282873
http://dx.doi.org/10.3390/toxins9030093
work_keys_str_mv AT yaoguorui crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh
AT lamkwokho crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh
AT perrykay crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh
AT weisemannjasmin crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh
AT rummelandreas crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh
AT jinrongsheng crystalstructureofthereceptorbindingdomainofbotulinumneurotoxintypehaalsoknownastypefaorh